Summary of Key Points Core Viewpoint - The company has recognized a total impairment loss of 8.71 million yuan for the first half of 2025, reflecting a cautious approach to accurately represent its financial condition [1][2]. Group 1: Impairment Loss Details - As of June 30, 2025, the company recorded a total of 8.71 million yuan in impairment losses, which includes 1.09 million yuan in credit impairment losses and 7.62 million yuan in asset impairment losses [1][2]. - The credit impairment loss primarily stems from bad debts related to accounts receivable and other receivables, calculated based on historical credit loss experience and current economic conditions [1]. - The asset impairment loss is attributed to inventory write-downs, where the cost of inventory exceeded its net realizable value, leading to a provision for inventory impairment [1]. Group 2: Impact on Financials - The total impairment provision of 8.71 million yuan will reduce the company's consolidated profit for the first half of 2025 by the same amount, not accounting for tax effects [2]. - The impairment provisions are in compliance with the relevant accounting standards and reflect the company's actual financial situation, indicating no significant impact on its operations [2].

证券代码：688085 证券简称：三友医疗 公告编号：2025-057 暂时补充流动资金的公告 （一）首次公开发行股票 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 包含募集资金及相关现金管理收益等，下文同。 上海三友医疗器械股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日 召开第四届董事会第二次会议，审议通过了《关于使用部分闲置募集资金暂时补 充流动资金的议案》，同意公司使用不超过 9,000.00 万元（含本数）闲置募集资 金（其中，首次公开发行股票募集资金 8,700 万元；发行股份及支付现金购买资 产并募集配套资金 300 万元）暂时补充流动资金，用于与公司主营业务相关的生 产经营使用，使用期限自公司董事会审议通过之日起不超过 12 个月，公司将随 时根据募投项目的进展及需求情况及时归还至募集资金专用账户。保荐机构及独 立财务顾问东方证券股份有限公司（以下简称"保荐机构"或"独立财务顾问"） 出具了无异议的核查意见。根据《上市公司募集资金监管规则》 经上海证券交易所科创板上市委员会 2020 年 ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-059 上海三友医疗器械股份有限公司 关于 2025 年度"提质增效重回报"行动方案半年度 评估报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为贯彻中央经济工作会议、中央金融工作会议精神，践行以投资者为本的 理念，落实上海证券交易所《关于开展科创板公司"提质增效重回报"专项行 动的倡议》，上海三友医疗器械股份有限公司（以下简称"公司"或"三友医 疗"）于 2025 年 5 月 24 日在上海证券交易所网站披露了《关于 2025 年度"提 质增效重回报"行动方案的公告》。根据 2025 年度行动方案，公司在 2025 年切 实履行"提质增效重回报"行动方案的具体举措，推动公司持续优化经营、规 范治理，切实履行上市公司的责任和义务，维护公司全体股东利益。公司认真 评估了 2025 年度行动方案实施效果，公司于 2025 年 8 月 22 日召开了第四届董 事会第二次会议审议通过了《关于<2025 年度"提质增效重回报"行动方案的 半年度评估报告>的议 ...

Fundraising Overview - The company raised a total of RMB 1,075,950,160.00 by issuing 51,333,500 shares at a price of RMB 20.96 per share, with a net amount of RMB 978,057,381.28 after deducting issuance costs [1][4] - As of March 5, 2025, the company raised RMB 213,999,988.12 by issuing 13,032,886 shares at a price of RMB 16.42 per share, resulting in a net amount of RMB 203,920,127.60 after deducting related costs [2][4] Fund Utilization - By June 30, 2025, the company had invested a total of RMB 89,883.02 million in fundraising projects, with RMB 538.30 million used in the current year [2][4] - The remaining balance of the fundraising account as of June 30, 2025, was RMB 4,168.62 million [2][4] Fund Management - The company established a fundraising management system in compliance with relevant laws and regulations to protect investor rights [3][4] - Special accounts for fundraising were opened at various banks, and a tripartite supervision agreement was signed with the sponsor and banks [3][4] Project Investment - The company reported that the funds were used for several projects, including the expansion of orthopedic implant production and the establishment of a research and development center [6][7] - None of the projects could independently account for their benefits due to their nature, which includes infrastructure improvements and marketing network expansions [6][7] Cash Management - The company approved the use of up to RMB 100 million of temporarily idle fundraising for cash management, ensuring it does not affect project construction [10][11] - As of June 30, 2025, the company had engaged in cash management with idle funds, generating a return of RMB 1.84 million [11] Adjustments and Compliance - The company has not used any excess funds for permanent working capital or loan repayments during the reporting period [10][15] - There were no violations in the use of fundraising, and the company has complied with disclosure obligations [12][15]

Core Viewpoint - The report highlights the significant growth in revenue and profit for Shanghai Sanyou Medical Co., Ltd. in the first half of 2025, driven by the increasing demand for orthopedic medical devices in the context of an aging population and rising healthcare awareness in China [4][6][9]. Company Overview - Shanghai Sanyou Medical Co., Ltd. focuses on the research, development, production, and sales of orthopedic implants and ultrasonic surgical devices [9][12]. - The company has established a strong brand presence in the spinal implant sector and is recognized for its innovative capabilities in product development [7][11]. Financial Performance - The company reported a revenue of approximately 249.76 million yuan for the first half of 2025, representing a year-on-year increase of 17.77% [4]. - The total profit reached approximately 40.42 million yuan, a significant increase of 648.18% compared to the same period last year [4]. - The net profit attributable to shareholders was approximately 36.60 million yuan, marking a remarkable growth of 2,083.64% year-on-year [4]. Market Trends - The orthopedic medical device market in China is expected to continue its stable growth, driven by an aging population and increasing prevalence of orthopedic diseases [6][9]. - The global orthopedic device market is projected to grow, with orthopedic medical devices accounting for about 9% of the total medical device market [6]. Product Development and Innovation - The company emphasizes original innovation in product development, focusing on meeting clinical needs and improving existing therapies [10][18]. - Recent advancements include the introduction of new materials and technologies in orthopedic implants, enhancing their mechanical strength and biocompatibility [8][10]. Strategic Acquisitions - The company completed the acquisition of the remaining minority stake in Water Wood Pavilion, which specializes in ultrasonic surgical devices, enhancing its product offerings and market position [12][13]. - A joint venture with a South Korean company was established to develop innovative cell biological materials, further strengthening the company's R&D capabilities [13]. International Expansion - The company has made significant progress in international markets, particularly in the U.S. and Europe, with successful product launches and increasing sales [16]. - The introduction of advanced surgical systems and technologies is expected to drive growth in these markets [16][17].

Core Points - Shanghai Sanyou Medical Devices Co., Ltd. reported a significant increase in revenue and profit for the first half of 2025, with operating income rising by 17.77% to CNY 249.76 million and total profit increasing by 648.18% to CNY 40.42 million [1] - The company's total assets at the end of the reporting period were CNY 2.31 billion, reflecting a slight increase of 0.32% compared to the previous year [1] Financial Summary - Total assets: CNY 2,314,136,752.55 at the end of the reporting period, up from CNY 2,306,660,250.83 [1] - Operating income: CNY 249,760,157.28, compared to CNY 212,076,101.08 in the same period last year, representing a 17.77% increase [1] - Total profit: CNY 40,424,190.71, a substantial increase from CNY 5,403,015.11, marking a 648.18% rise [1] - Net profit attributable to shareholders: CNY 26,024,141.93, compared to a loss of CNY 1,816,185.53 in the previous year [1] - Net cash flow from operating activities: CNY -8,070,534.49, an improvement from CNY -15,431,761.97 [1] Shareholder Information - Total number of shareholders as of the reporting period: 7,108 [2] - Major shareholders include QM5 LIMITED with 14.74% and Xu Nong with 11.78% [2][3] - The company has established a concerted action relationship among major shareholders, including Xu Nong, Michael Mingyan Liu, and David Fan [3]

上海三友医疗器械股份有限公司董事会薪酬与考核委员会 关于公司 2025 年限制性股票激励计划（草案）的核查意见 上海三友医疗器械股份有限公司（以下简称"公司"）董事会薪酬与考核委 员会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》 （以下简称"《证券法》"）、 《上市公司股权激励管理办法》 （四）法律法规规定不得实行股权激励的； （五）中国证监会认定的其他情形。 公司具备实施股权激励计划的主体资格。 二、公司 2025 年限制性股票激励计划（以下简称"本激励计划"）所确定的 激励对象不存在下列情形： （以下简称 "《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市 规则》"）、《科创板上市公司自律监管指南第 4 号——股权激励信息披露》（以下 简称"《自律监管指南》"）等相关法律、法规及规范性文件和《上海三友医疗器 械股份有限公司章程》（以下简称"《公司章程》"）的有关规定，对公司《2025 年限制性股票激励计划（草案） 》（以下简称"《激励计划（草案）》"）进行了核 查，发表核查意见如下： 一、公司不存在《管理办法》等法律、法规及规范性文件规定的禁止 ...

Meeting Information - The shareholders' meeting is scheduled for September 12, 2025, at 14:00 [1] - The meeting will be held at the company's conference room located at 385 Hui Rong Road, Jiading Industrial Zone, Shanghai [1] - Voting will be conducted through a combination of on-site and online methods [1] Voting Procedures - The online voting system used will be the Shanghai Stock Exchange shareholders' meeting online voting system [2] - Voting will be available from 9:15 to 15:00 on the day of the meeting [1][2] - Shareholders must complete identity verification to vote via the internet [2] Agenda Items - The meeting will review several proposals, including the management assessment method and matters related to the restricted stock incentive plan [2] - All proposals have been approved by the company's board meeting held on August 22, 2025 [2] Attendance Requirements - Shareholders registered by the close of trading on September 5, 2025, are eligible to attend the meeting [4] - Shareholders can appoint a proxy to attend and vote on their behalf [4] Registration Details - Registration for the meeting will take place on September 8, 2025, from 9:00 to 17:00 [5] - Registration can be done via mail or fax, and must be completed by the specified deadline [5] Contact Information - For inquiries, shareholders can contact Ms. Wang at 021-58266088 [5]

东方证券股份有限公司 关于上海三友医疗器械股份有限公司 使用部分闲置募集资金暂时补充流动资金的 核查意见 东方证券股份有限公司（以下简称"东方证券"或"独立财务顾问"）作为 上海三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"）发行股份 及支付现金购买资产并募集配套资金暨关联交易的独立财务顾问，根据《证券发 行上市保荐业务管理办法》 《上市公司募 集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等法律 范运作》 法规的相关规定，对三友医疗本次拟使用部分闲置募集资金暂时补充流动资金事 项进行了专项核查，具体核查情况如下： 一、募集资金基本情况 经上海证券交易所并购重组审核委员会 2024 年 12 月 30 日审核同意，并经 中国证券监督管理委员会于 2025 年 1 月 17 日《关于同意上海三友医疗器械股份 有限公司发行股份购买资产并募集配套资金注册的批复》 （证监许可〔2025〕109 号）同意注册，公司获准向特定对象发行人民币普通股 13,032,886 股，每股面值 人民币 1.00 元，每股发行价为人民 ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-061 上海三友医疗器械股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ?股权激励方式：限制性股票（第二类限制性股票） ?股份来源：上海三友医疗器械股份有限公司（以下简称"公司"）自二级 市场回购的公司 A 股普通股股票及/或向激励对象定向发行的公司 A 股普通股股 票。 ?股权激励的权益总数及涉及的标的股票总数：《上海三友医疗器械股份有 限公司 2025 年限制性股票激励计划（草案）》（以下简称"本激励计划"）拟向 激励对象授予 478.20 万股限制性股票，约占本激励计划草案公告时公司股本总 额 33,346.2498 万股的 1.43%。本次授予为一次性授予。 一、本激励计划的目的与原则 为了进一步健全公司长效激励机制，吸引和留住优秀人才，充分调动公司员 工的积极性，有效地将股东利益、公司利益和核心团队个人利益结合在一起，使 各方共同关注公司的长远发展，在充分保障股东利益的前提下，按照收益与贡献 对等的原则，根据《中华人民共 ...